Vanda Pharmaceuticals Inc.
VNDA
$6.42
$0.152.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -441.37% | -1,066.53% | -413.78% | -512.58% | -805.05% |
| Total Depreciation and Amortization | 29.40% | 30.24% | 44.03% | 76.27% | 127.94% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,454.64% | 91,897.96% | -242.15% | -982.62% | -252.69% |
| Change in Net Operating Assets | 115.13% | 226.68% | 234.65% | 381.37% | 2.27% |
| Cash from Operations | -124.02% | -594.56% | -363.12% | -1,160.40% | -393.95% |
| Capital Expenditure | 67.95% | 78.85% | 98.95% | 98.95% | 97.64% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 52.71% | 854.13% | 37.00% | -27.72% | 141.40% |
| Cash from Investing | 59.30% | 644.23% | 182.79% | 206.55% | 120.54% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -318.09% | -1,184.52% | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 100.00% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -59.43% | -1,774.84% | -- | -- | -- |
| Foreign Exchange rate Adjustments | 17.00% | 114.11% | -205.29% | 5,000.00% | -733.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -332.29% | 47.87% | 63.15% | 53.33% | 94.17% |